Orthofix Medical (OFIX) opened 2026 by reporting Q1 results that sit against a recent run of quarterly losses, with Q4 2025 revenue at US$219.9 million and a basic EPS loss of US$0.06 on net income loss of US$2.2 million. The trailing twelve months show revenue of US$822.3 million against a basic EPS loss of US$2.33 and a net income loss of US$92.2 million. Over recent quarters, the company has seen revenue move from US$193.6 million in Q1 2025 to US$219.9 million in Q4 2025, while quarterly basic EPS losses narrowed from US$1.35 to US$0.06. This has set up an earnings season where investors are focused on how much of that top line is translating into sustainable margins.

See our full analysis for Orthofix Medical.

With the latest figures on the table, the next step is to compare these results with the prevailing narratives about Orthofix Medical’s growth prospects and path toward profitability to see which storylines hold up and which are pushed back.

Losses Shrink, But Profitability Still Out Of Reach

• Over the last four reported quarters, net income loss narrowed from US$53.1 million in Q1 2025 to US$2.2 million in Q4 2025, while trailing twelve month losses sit at US$92.2 million on US$822.3 million of revenue.
• Bulls point to this pattern of smaller quarterly losses as early evidence of an earnings turnaround. However, forecasts that Orthofix is not expected to be profitable within the next three years keep that story very much unfinished.
  • The bullish narrative talks about EBITDA margin expansion and higher margin product launches, but the trailing twelve month basic EPS is still a loss of US$2.33, which shows that any efficiency gains have not translated into positive earnings yet.
  • Supporters arguing for a future margin lift need to weigh that optimism against five year losses that have grown at 32.5% per year, which is a very different trend from the recent quarter to quarter improvement.

Bulls arguing that new platforms and margin gains could eventually justify higher earnings should look closely at how the recent loss trends align with that story before leaning too hard on it. 🐂 Orthofix Medical Bull Case

6% Revenue Growth Versus Persistent Losses

• Revenue has grown around 6% per year over the past five years, with quarterly sales in 2025 moving between US$193.6 million and US$219.9 million, yet trailing twelve month net income remains a loss of US$92.2 million.
• Bears focus on this mix of modest top line growth and deepening long term losses, arguing that a 6% revenue growth rate is not enough to offset a multi year loss expansion of 32.5% per year.
  • The cautious narrative also highlights that revenue is forecast to grow slower than the broader US market at 11.2%, so Orthofix is working with a growth rate that is lower than the market benchmark while still carrying sizeable losses.
  • On top of this, the company is not forecast to become profitable over the next three years, which directly supports the bearish view that current growth has not yet laid out a clear path to sustainable earnings.

Anyone worried that growth might not be enough to close the earnings gap will find plenty in these multi year loss and revenue figures that lines up with the cautious view. 🐻 Orthofix Medical Bear Case

Low 0.6x P/S Against DCF Fair Value Of US$43.38

• At a share price of US$12.44 and a P/S ratio of 0.6x versus peer and industry averages of 3.3x and 2.8x, the stock is also assessed as trading well below a DCF fair value of about US$43.38 and an analyst price target of US$17.25.
• Consensus narrative supporters see this valuation gap as a potential reward. However, it sits alongside clear risks around ongoing losses and insider selling that complicate the picture.
  • The discount relative to the DCF fair value and the analyst target suggests the market is pricing in the unprofitable status and the expectation that profitability is not anticipated in the next three years, even while analysts model higher future margins.
  • Recent significant insider selling over the past three months adds another data point that cautious investors may factor in when comparing the low 0.6x P/S multiple with the higher DCF and target values.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Orthofix Medical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, does this mixed picture match your own read of Orthofix Medical, or raise new questions for you? Take a closer look at the numbers, weigh the red flags against the potential upside, and then check out the 3 key rewards and 2 important warning signs

Explore Alternatives

Orthofix Medical carries ongoing losses, forecasts do not point to profitability within three years, and modest 6% revenue growth sits alongside a 32.5% annual loss expansion.

If you want ideas where the business profile targets steadier earnings and fewer red flags, check out our 72 resilient stocks with low risk scores to quickly spot candidates that may better match that preference.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.